NCT03139253

Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Yanqing Li · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.

Conditions

• Antimicrobial Susceptibility Testing
• Triple Therapy

Interventions

Type	Name	Description
DRUG	amoxicillin	amoxicillin 1000 mg bid. for 14 days
DRUG	clarithromycin	clarithromycin 500 mg bid. for 14 days.
DRUG	tinidazole	tinidazole 500 mg bid. for 14 days.
DRUG	levofloxacin	levofloxacin 500 mg qd. for 14 days.
DRUG	furazolidone	furazolidone 100 mg bid. for 14 days.
DRUG	tetracycline	tetracycline 750 mg bid. for 14 days.
DRUG	Ilaprazole	Ilaprazole 5 mg bid. for 14 days.

Timeline

• Start date: 2017-05-30
• Primary completion: 2017-06-30
• Completion: 2017-06-30
• First posted: 2017-05-03
• Last updated: 2017-05-03